Biblio

Author Title [ Type

] Year

Filters: Author is Schaap, Nicolaas P M [Clear All Filters]

Journal Article

Sijs-Szabo A, Dinmohamed AG, Versluis J, van der Holt B, Bellido M, Hazenberg MD, van Gelder M, Schaap NPM, Meijer E, van der Wagen LE, et al. Allogeneic Stem Cell Transplantation in Patients >40 Years of Age With Acute Lymphoblastic Leukemia: Reduced Intensity Versus Myeloablative Conditioning. Transplantation. 2023.

van Groningen LFJ, Liefferink AM, de Haan AFJ, Schaap NPM, J Donnelly P, Blijlevens NMA, van der Velden WJFM. Combination therapy with inolimomab and etanercept for severe steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2015.

Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NPM, Finke J, Robin M, Fedele R, Bron D, et al. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica. 2014.

Penack O, Luft T, Peczynski C, Benner A, Sica S, Arat M, Itälä-Remes M, Corral LLopez, Schaap NPM, Karas M, et al. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study. J Immunother Cancer. 2024;12(1).

van Hauten PMM, Hooijmaijers L, Vidal-Manrique M, van der Waart AB, Hobo W, Wu J, Blijlevens NMA, Jansen JH, Walcheck B, Schaap NPM, et al. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity. Cytotherapy. 2023.

van der Sluijs Jvan Eck, van Ens D, Brummelman J, Heister D, Sareen A, Truijen L, Schenau DS van Inge, Heemskerk MHM, Griffioen M, Kester MGD, et al. Human CD34-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8 T cell and NK cell responses in vitro and in vivo. Cell Mol Life Sci. 2023;80(10):298.

Groth C, van Groningen LFJ, Matos TR, Bremmers ME, Preijers FWMB, Dolstra H, Reicherts C, Schaap NPM, van Hooren EHG, IntHout J, et al. Phase I/II trial of a combination of anti-CD3/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2018.